Highly rated in
Highly rated in
Check Dr. Donald B. Kohn's experience treating your condition:
About Dr. Donald B. Kohn

Donald Kohn is a Pediatric Hematologist Oncology specialist and a Pediatrics expert in Los Angeles, California. Kohn is highly rated in 16 conditions, according to our data. His top areas of expertise are Adenosine Deaminase Deficiency, Severe Combined Immunodeficiency (SCID), Bare Lymphocyte Syndrome, Omenn Syndrome, and Bone Marrow Transplant. He is licensed to treat patients in California. Kohn is currently accepting new patients.

His clinical research consists of co-authoring 175 peer reviewed articles and participating in 11 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Donald B. Kohn it is best to call his office and ask if your insurance is accepted.

Dr. Donald B. Kohn accepts the following insurance:

  •  Ambetter
200 Ucla Medical Plz, Los Angeles, CA 90095
Background & Education
Pediatric Hematology Oncology
Pediatric Hematology-Oncology in CA
Hospital Affiliations
Ronald Reagan UCLA Medical Center
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Clinical Research Study of Autologous Stem Cell Transplantation for Sickle Cell Disease (SCD) Using Peripheral Blood CD34+ Cells Modified With the Lenti/G-βAS3-FB Lentiviral Vector
A Two-Part, Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
Multi-site Phase I/II Trial Evaluating the Treatment of SCID-X1 Patients With Retrovirus-mediated Gene Transfer
A Phase I Clinical Trial for Gene Therapy in Infantile Malignant Osteopetrosis (IMO) to Evaluate the Safety and Preliminary Efficacy of Autologous CD34+ Enriched Cells Transduced With a LV Vector Encoding the TCIRG1 Gene
Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
View 10 Less Clinical Trials -

176 Total Publications

Diverse Approaches to Gene Therapy of Sickle Cell Disease.

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors